Croma-Pharma unveils new toxin
As of January 25, aesthetic manufacturer Croma-Pharma has confirmed completion of the decentralised procedure for its new botulinum toxin.
As of January 25, aesthetic manufacturer Croma-Pharma has confirmed completion of the decentralised procedure for its new botulinum toxin.
Biopharmaceutical company Hugel America and aesthetic manufacturer Croma-Pharma has unveiled that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for letibotulinumtoxinA as a treatment for glabellar lines.
Pharmaceutical company Croma Pharma has rebranded its hyaluronic acid filler brand Princess to saypha.